Novel combination treatment outperforms standard therapy in patients with EGFR NSCLC
The combination of the antibody amivantamab and lazertinib, a drug targeting EGFR, shows better clinical benefits compared to standard treatment ...
Tag: Docetaxel
Amgen plows ahead with costly, highly toxic cancer dosing despite FDA challenge
When doctors began using the drug sotorasib in 2021 with high expectations for its innovative approach to attacking lung cancer, ...
